This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
MyBioSource
product type :
ELISA/assay
product name :
Porcine Vascular Endothelial Growth Factor A (VEGFA) ELISA Kit
catalog :
MBS9309220
quantity :
48-Strip-Wells
price :
470 USD
product information
catalog number :
MBS9309220
products type :
ELISA Kit
products full name :
Porcine Vascular Endothelial Growth Factor A (VEGFA) ELISA Kit
products short name :
[Vascular Endothelial Growth Factor A (VEGFA)]
other names :
[vascular endothelial growth factor A isoform p; Vascular endothelial growth factor A; vascular endothelial growth factor A; vascular permeability factor; vascular endothelial growth factor A; Vascular permeability factor]
products gene name :
[VEGFA]
other gene names :
[VEGFA; VEGFA; VPF; VEGF; MVCD1; VEGF; VEGF-A; VPF]
uniprot entry name :
VEGFA_HUMAN
reactivity :
Porcine
specificity :
No significant cross-reactivity or interference between this analyte and analogues is observed.
storage stability :
Store all reagents at 2-8 degree C
other info1 :
Assay Type: Quantitative Sandwich. Detection Range: 62.5 pg/ml - 2000 pg/ml. Sensitivity: 10 pg/ml.
other info2 :
Intra-assay Precision: Intra-assay CV (%) is less than 15%. Inter-assay Precision: Inter-assay CV (%) is less than 15%. [CV(%) = SD/mean ×100].
products description :
Background/Introduction: This Quantitative Sandwich ELISA kit is only for in vitro research use only, not for drug, household, therapeutic or diagnostic applications! This kit is intended to be used for determination the level of VEGF-A (hereafter termed "analyte") in undiluted original Porcine body fluids, tissue homogenates, secretions or feces samples. This kit is NOT suitable for assaying non-biological sources of substances.
ncbi gi num :
284172473
ncbi acc num :
NP_001165101.1
ncbi gb acc num :
NM_001171630.1
uniprot acc num :
P15692
ncbi mol weight :
27,042 Da
ncbi pathways :
Angiogenesis Pathway (198772); Bladder Cancer Pathway (83115); Bladder Cancer Pathway (527); Cellular Response To Hypoxia Pathway (645259); Cellular Responses To Stress Pathway (645258); Cytokine-cytokine Receptor Interaction Pathway (83051); Cytokine-cytokine Receptor Interaction Pathway (460); Endochondral Ossification Pathway (198812); Focal Adhesion Pathway (83067); Focal Adhesion Pathway (478)
ncbi summary :
This gene is a member of the PDGF/VEGF growth factor family and encodes a protein that is often found as a disulfide linked homodimer. This protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Elevated levels of this protein is linked to POEMS syndrome, also known as Crow-Fukase syndrome. Mutations in this gene have been associated with proliferative and nonproliferative diabetic retinopathy. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. There is also evidence for the use of non-AUG (CUG) translation initiation sites upstream of, and in-frame with the first AUG, leading to additional isoforms. [provided by RefSeq, Jul 2008]
uniprot summary :
VEGF iso14: Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. Defects in VEGFA are a cause of susceptibility to microvascular complications of diabetes type 1 (MVCD1). These are pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis. Belongs to the PDGF/VEGF growth factor family. 13 isoforms of the human protein are produced by alternative promoter. Protein type: Motility/polarity/chemotaxis; Secreted; Cytokine; Secreted, signal peptide. Chromosomal Location of Human Ortholog: 6p12. Cellular Component: proteinaceous extracellular matrix; extracellular space; cell surface; membrane; cytoplasm; extracellular region; secretory granule. Molecular Function: heparin binding; identical protein binding; protein homodimerization activity; growth factor activity; extracellular matrix binding; platelet-derived growth factor receptor binding; cytokine activity; vascular endothelial growth factor receptor 1 binding; vascular endothelial growth factor receptor binding; receptor agonist activity; protein binding; vascular endothelial growth factor receptor 2 binding; protein heterodimerization activity; fibronectin binding; chemoattractant activity. Biological Process: heart morphogenesis; positive regulation of cell adhesion; macrophage differentiation; positive regulation of positive chemotaxis; positive regulation of leukocyte migration; positive regulation of receptor internalization; cell maturation; basophil chemotaxis; regulation of cell shape; positive regulation of MAP kinase activity; positive chemotaxis; positive regulation of mesenchymal cell proliferation; mesoderm development; kidney development; platelet activation; positive regulation of neuroblast proliferation; nervous system development; monocyte differentiation; positive regulation of blood vessel endothelial cell migration; activation of CREB transcription factor; positive regulation of protein amino acid autophosphorylation; positive regulation of vascular permeability; patterning of blood vessels; regulation of transcription from RNA polymerase II promoter; positive regulation of angiogenesis; positive regulation of peptidyl-tyrosine phosphorylation; eye photoreceptor cell development; camera-type eye morphogenesis; cell migration during sprouting angiogenesis; branching morphogenesis of a tube; cardiac muscle fiber development; positive regulation of cell division; positive regulation of axon extension involved in axon guidance; activation of protein kinase activity; positive regulation of transcription from RNA polymerase II promoter; positive regulation of endothelial cell proliferation; regulation of cGMP metabolic process; surfactant homeostasis; positive regulation of epithelial cell proliferation; negative regulation of apoptosis; lactation; post-embryonic camera-type eye development; negative regulation of transcription from RNA polymerase II promoter; negative regulation of caspase activity; positive regulation of vascular endothelial growth factor receptor signaling pathway; induction of positive chemotaxis; platelet degranulation; positive regulation of focal adhesion formation; epithelial cell differentiation; ovarian follicle development; positive regulation of cell proliferation; angiogenesis; vasculogenesis; in utero embryonic development; lumen formation; positive regulation of cell motility; positive regulation of peptidyl-serine phosphorylation; positive regulation of protein complex assembly; response to hypoxia; artery morphogenesis; positive regulation of protein amino acid phosphorylation; blood coagulation; vascular endothelial growth factor receptor signaling pathway; growth; positive regulation of cell migration; lung development. Disease: Microvascular Complications Of Diabetes, Susceptibility To, 1
size1 :
48-Strip-Wells
price1 :
470 USD
size2 :
96-Strip-Wells
price2 :
680
size3 :
5x96-Strip-Wells
price3 :
3100
size4 :
10x96-Strip-Wells
price4 :
6095
company information
MyBioSource
P.O. Box 153308
San Diego, CA 92195-3308
sales@mybiosource.com
https://www.mybiosource.com
1-888-627-0165
headquarters: USA
MyBioSource, LLC was orginally founded in Vancouver by three enthusiastic scientists who are passionate about providing the world with the best reagents available. Together, they form a company with a big vision known as MyBioSource. MyBioSource is now located in San Diego, California, USA.

"MyBioSource's number 1 vision is to be the world's number 1 quality reagents provider."

Our goal is to provide researchers, scientists and customers alike with a one-stop-shop for all of their reagents needs, whether it is monoclonal antibody, polyclonal antibody, recombinant protein, peptide, etc...

"MyBioSource offers the best products at unbeatable prices."

Please spend a few minutes to browse our online catalogs and see the wide range of products available. We ship our products through our shipping/distribution facility in San Diego, California, USA.

Would you like to receive email and e-newsletter from MyBioSource about new products, special offers and events? Please click here to join our Mailing List!